231 related articles for article (PubMed ID: 19047130)
1. Targeting the stroma by T cells to limit tumor growth.
Zhang B
Cancer Res; 2008 Dec; 68(23):9570-3. PubMed ID: 19047130
[TBL] [Abstract][Full Text] [Related]
2. Equilibrium between host and cancer caused by effector T cells killing tumor stroma.
Zhang B; Zhang Y; Bowerman NA; Schietinger A; Fu YX; Kranz DM; Rowley DA; Schreiber H
Cancer Res; 2008 Mar; 68(5):1563-71. PubMed ID: 18316622
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy: target the stroma to hit the tumor.
Kammertoens T; Schüler T; Blankenstein T
Trends Mol Med; 2005 May; 11(5):225-31. PubMed ID: 15882610
[TBL] [Abstract][Full Text] [Related]
4. Antigen choice in adoptive T-cell therapy of cancer.
Offringa R
Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
[TBL] [Abstract][Full Text] [Related]
5. Genetic redirection of T cells for cancer therapy.
Westwood JA; Kershaw MH
J Leukoc Biol; 2010 May; 87(5):791-803. PubMed ID: 20179152
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ.
Textor A; Listopad JJ; Wührmann LL; Perez C; Kruschinski A; Chmielewski M; Abken H; Blankenstein T; Charo J
Cancer Res; 2014 Dec; 74(23):6796-805. PubMed ID: 25297631
[TBL] [Abstract][Full Text] [Related]
7. Intrinsic modulation of lymphocyte function by stromal cell network: advance in therapeutic targeting of cancer.
Görgün G; Anderson KC
Immunotherapy; 2011 Oct; 3(10):1253-64. PubMed ID: 21995575
[TBL] [Abstract][Full Text] [Related]
8. Cellular therapy to control tumor progression.
Kapp M; Rasche L; Einsele H; Grigoleit GU
Curr Opin Hematol; 2009 Nov; 16(6):437-43. PubMed ID: 19587587
[TBL] [Abstract][Full Text] [Related]
9. Effects of the tumor microenvironment on the efficacy of tumor immunotherapy.
Neeson P; Paterson Y
Immunol Invest; 2006; 35(3-4):359-94. PubMed ID: 16916758
[TBL] [Abstract][Full Text] [Related]
10. Adoptive T-cell therapy of cancer.
Yee C
Hematol Oncol Clin North Am; 2006 Jun; 20(3):711-33. PubMed ID: 16762731
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer.
Gross S; Walden P
Immunol Lett; 2008 Feb; 116(1):7-14. PubMed ID: 18164076
[TBL] [Abstract][Full Text] [Related]
12. The role of tumor stroma in the interaction between tumor and immune system.
Blankenstein T
Curr Opin Immunol; 2005 Apr; 17(2):180-6. PubMed ID: 15766679
[TBL] [Abstract][Full Text] [Related]
13. Making and circumventing tolerance to cancer.
Kammertoens T; Blankenstein T
Eur J Immunol; 2009 Sep; 39(9):2345-53. PubMed ID: 19634191
[TBL] [Abstract][Full Text] [Related]
14. Tumor reactive T cells get a boost.
Pardoll DM
Nat Biotechnol; 2002 Dec; 20(12):1207-8. PubMed ID: 12454671
[No Abstract] [Full Text] [Related]
15. Antitumor activity and some immunological properties of gammadelta T-cells from patients with gastrointestinal carcinomas.
Murayama M; Tanaka Y; Yagi J; Uchiyama T; Ogawa K
Anticancer Res; 2008; 28(5B):2921-31. PubMed ID: 19031935
[TBL] [Abstract][Full Text] [Related]
16. [Molecular targets for development of cancer immunotherapy].
Kawakami Y
Nihon Rinsho; 2012 Nov; 70 Suppl 8():144-8. PubMed ID: 23513828
[No Abstract] [Full Text] [Related]
17. Optimizing T-cell expansion: have we reached the limit?
Melenhorst JJ
Cytotherapy; 2009; 11(7):813-4. PubMed ID: 19903094
[No Abstract] [Full Text] [Related]
18. Preclinical development of T cell receptor gene therapy.
Bendle GM; Haanen JB; Schumacher TN
Curr Opin Immunol; 2009 Apr; 21(2):209-14. PubMed ID: 19321326
[TBL] [Abstract][Full Text] [Related]
19. The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum.
Westwood JA; Murray WK; Trivett M; Haynes NM; Solomon B; Mileshkin L; Ball D; Michael M; Burman A; Mayura-Guru P; Trapani JA; Peinert S; Hönemann D; Miles Prince H; Scott AM; Smyth MJ; Darcy PK; Kershaw MH
J Immunother; 2009 Apr; 32(3):292-301. PubMed ID: 19242371
[TBL] [Abstract][Full Text] [Related]
20. Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses.
de Souza AP; Bonorino C
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1317-32. PubMed ID: 19761435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
